Cristóbal Quevedo Ignacio, Piró Manuel, Matey Sonia, Álvarez Abigail, Toribio Mónica, Guillén Alfredo, García-Velasco Juan A
Department of Gynecology, Hospital Clínico San Carlos, 28040 Madrid, Spain.
IVIRMA Global Research Alliance, 28023 Madrid, Spain.
J Clin Med. 2025 Jun 11;14(12):4150. doi: 10.3390/jcm14124150.
This research aimed to study the effect of 15mcg/day of follitropin delta on normo-responding women. : A single-center, open-label, matched case-control pilot trial was carried out from September 2021 to June 2022. In this trial, normo-responding oocyte donors were given 15 mcg/day of follitropin delta or 225 IU/day of follitropin alfa, as well as medroxyprogesterone acetate for pituitary suppression during the cycle. The main outcome measured was the number of oocytes retrieved. : A fixed dose of 15 mcg/day of follitropin delta for ovarian stimulation in normo-responders achieved an average of 17 oocytes retrieved. No differences were observed vs. 225 IU/day of follitropin alfa in the number of oocytes [17.8 ± 7.8 vs. 18.5 ± 7.7, respectively, = 0.156], the number of metaphase II oocytes [13.5 ± 6.9 vs. 15 ± 6.3, = 0.105], the fertilization rates (71.1% vs. 72.9%, = 0.523), the number of usable blastocysts (4.9 ± 2.4 vs. 4.5 ± 2.5, = 0.466), and the implantation rate (64% vs. 57%, = 0.575). In the follitropin delta group, the duration of the stimulation was significantly shorter (9.4 ± 1.2 vs. 10.9 ± 1.2, < 0.01), and the overall gonadotropin intake was lower. There were no clinically relevant differences between treatment groups regarding the safety profile. Global patient satisfaction with the follitropin delta ovarian stimulation was very high (7.7 ± 2.2). : A daily dose of 15 mcg of follitropin delta may provide a similar ovarian response to 225 IU/day of follitropin alfa; aiming to retrieve 17 oocytes in normo-responders undergoing progestin-primed ovarian stimulation, it could reduce gonadotropin intake by reducing the duration of the stimulation cycle, with a possible high patient satisfaction level.
本研究旨在探讨每日15微克的δ-促卵泡素对反应正常的女性的影响。：于2021年9月至2022年6月开展了一项单中心、开放标签、匹配病例对照的试点试验。在该试验中，给反应正常的卵母细胞捐赠者每日注射15微克的δ-促卵泡素或每日225国际单位的α-促卵泡素，并在周期中给予醋酸甲羟孕酮以抑制垂体功能。主要测量的结果是获取的卵母细胞数量。：对于反应正常者，固定剂量每日15微克的δ-促卵泡素用于卵巢刺激时，平均获取17个卵母细胞。在卵母细胞数量[分别为17.8±7.8和18.5±7.7，P=0.156]、中期II卵母细胞数量[13.5±6.9和15±6.3，P=0.105]、受精率（71.1%对72.9%，P=0.523）、可用囊胚数量（4.9±2.4和4.5±2.5，P=0.466）以及着床率（64%对57%，P=0.575）方面，与每日225国际单位的α-促卵泡素相比未观察到差异。在δ-促卵泡素组中，刺激持续时间显著更短（9.4±1.2对10.9±1.2，P<0.01），且促性腺激素的总体摄入量更低。治疗组之间在安全性方面无临床相关差异。患者对δ-促卵泡素卵巢刺激的总体满意度非常高（7.7±2.2）。：每日剂量15微克δ-促卵泡素可能产生与每日225国际单位α-促卵泡素相似的卵巢反应；对于接受孕激素预处理卵巢刺激的反应正常者，旨在获取17个卵母细胞时，它可通过缩短刺激周期来减少促性腺激素的摄入量，且患者满意度可能较高。
